Shares of the Mumbai-based company fell as much as 5.8% on Monday after local media reports said the Drug Controller General of India (DCGI) pulled up Glenmark regarding the price of the tablet and other concerns.
Glenmark defends price of its COVID-19 drug favipiravir version after DCGI sends notice
